Pictured at the Molecular Medicine Ireland CSFP Annual Meeting were: Dr Mark Watson (MMI), Professor Sherine Gabriel (Mayo Clinic), Dr Christine Dingivan (PPD Inc.), Dr Ruth Barrington (MMI) and Professor Matthew Griffin (REMEDI, NUI Galway).
Fellows of the groundbreaking Molecular Medicine Ireland (MMI) Clinician Scientist Fellowship Programme (CSFP) have presented their research findings at the programme’s first annual meeting which took place this month at NUI Galway.
The programme is training the next generation of clinician scientists with the unique and specialised knowledge essential to fulfil Ireland’s research needs in translational medicine.
‘Today is a milestone in the Clinician Scientist Fellowship programme’ commented Dr Ruth Barrington, CEO of MMI. ‘The research presented by the Fellows is at the cutting edge of science and is of great significance for more effective diagnosis of disease and treatment of patients. The Fellows are contributing to Ireland’s reputation for excellence in clinical and translational research. They are also making Ireland a more attractive place for investment by healthcare industries in research and development’, she said.
Prof Sherine Gabriel, Professor of Medicine and Epidemiology at the internationally renowned Mayo Clinic, delivered the keynote lecture at the meeting entitled ‘Heart Disease and Premature Death in Rheumatoid Arthritis: Lessons from Epidemiology’.
Fellows from five institutions including UCD, who have a shared agenda in clinical and translational research, are participating in the CSFP which is coordinated by Molecular Medicine Ireland. This training programme transcends institutional boundaries and provides training for this group of clinician researchers through a structured PhD programme. 22 MMI Fellows have been appointed to date.
The CSFP is funded by the Irish Government under the Programme for Research in Third Level Institutions Cycle 4.
